PRN1371

PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively[1].

Product Specifications

CAS Number

[1802929-43-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Fms; FGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PRN1371.html

Purity

99.78

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1C(C2=C(Cl)C(OC)=CC(OC)=C2Cl)=CC3=CN=C(NC)N=C3N1CCCN4CCN(C(C=C)=O)CC4

Molecular Formula

C26H30Cl2N6O4

Molecular Weight

561.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Brameld KA, et al. Discovery of the Irreversible Covalent FGFR Inhibitor 8- (3- (4-Acryloylpiperazin-1-yl) propyl) -6- (2,6-dichloro-3,5-dimethoxyphenyl) -2- (methylamino) pyrido[2,3-d]pyrimidin-7 (8H) -one (PRN1371) for the Treatment of Solid Tumors. J Med Chem. 2017 Aug 10;60 (15) :6516-6527.